In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
November 8th, 2004 | 25 | No |
Popular Name: Rosiglitazone Rosiglitazone
Find On: PubMed — Wikipedia — Google
CAS Numbers: 1217260-35-9 , 122320-73-4 , 155141-29-0 , 302543-62-0 , 316371-83-2 , 316371-84-3 , [122320-73-4] , [155141-29-0] , [302543-62-0]
122320-73-4; D08491; Gaudil (TN); Rosiglitazone (INN)
155141-29-0; Avandia (TN); D00596; Rosiglitazone maleate (JAN/USAN)
2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-
2,4-thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; BRL-49653
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione
5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydrochloride
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[4-[2-[methyl(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-quinone
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methyl]-2,4-thiazolidine-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
Avandia;Rosiglitazone maleate;Rosiglizole
BRL 49653C; rosiglitazone maleate
BRL-49653; BRL-49653-C; BRL-49653C
CPD000471612; ROSIGLITAZONE MALEATE
CPD000471612; ROSIGLITAZONE MALEATE; SAM001246610
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
INN); Rosiglitazone maleate (FDA
INN); Rosiglitazone Maleate (USAN
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 2.35 | 7.4 | -33.54 | 2 | 6 | 1 | 73 | 358.443 | 7 | ↓ |
Mid Mid (pH 6-8) | 2.35 | 7.28 | -11.07 | 1 | 6 | 0 | 72 | 357.435 | 7 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 3.80e-02 g/l | DrugBank-approved |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
Purity | 95% | Fluorochem |
Purity | 98% | Fluorochem |
UniProt Database Links | ABHDB_MOUSE; CIDEA_MOUSE; CIDEC_MOUSE; PLPL2_RAT | ChEBI |
Therapy | antidiabetic | SMDC MicroSource |
Patent Database Links | EP1088824; EP1136071; EP1254667; EP1258253; EP1338600; EP1354882; EP1391460; EP1411055; EP1468997; EP1491541; EP1493448; EP1514550; EP1522310; EP1537858; EP1538164; EP1559710; EP1595544; EP1607396; EP1625847; EP1634605; EP1642593; EP1652913; EP1688148; EP | ChEBI |
Patent Database Links | EP1468997; EP1553091; EP1854794; EP1884513; US2005014798; US2006264639; US2007225337; US2007265313; WO2005095390; WO2005105794; WO2006010653; WO2006125402 | ChEBI |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : Sequoia Research Products Ltd.; NCC_SUPPLIER_STRUCTURE_ID : SRP01315r; 1 maleic acid | NIH Clinical Collection via PubChem |
Target | PPAR | Selleck Chemicals |
Reactome Database Links | REACT_15291; REACT_19346; REACT_19366; REACT_21412; REACT_22263; REACT_22436; REACT_27257 | ChEBI |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: Sequoia Research Products Ltd.; SUPPLIER_STRUCTURE_ID: SRP01315r; SALT: 1 maleic acid | NIH Clinical Collection via PubChem |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AOFB-2-E | Monoamine Oxidase B (cluster #2 Of 8), Eukaryotic | Eukaryotes | 832 | 0.34 | Binding ≤ 10μM |
PPARA-1-E | Peroxisome Proliferator-activated Receptor Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 4100 | 0.30 | Binding ≤ 10μM |
PPARD-2-E | Peroxisome Proliferator-activated Receptor Delta (cluster #2 Of 2), Eukaryotic | Eukaryotes | 3620 | 0.30 | Binding ≤ 10μM |
PPARG-1-E | Peroxisome Proliferator-activated Receptor Gamma (cluster #1 Of 2), Eukaryotic | Eukaryotes | 14 | 0.44 | Binding ≤ 10μM |
PPARG-1-E | Peroxisome Proliferator-activated Receptor Gamma (cluster #1 Of 2), Eukaryotic | Eukaryotes | 60 | 0.40 | Binding ≤ 10μM |
RARG-1-E | Retinoic Acid Receptor Gamma (cluster #1 Of 2), Eukaryotic | Eukaryotes | 10000 | 0.28 | Binding ≤ 10μM |
RXRA-1-E | Retinoid X Receptor Alpha (cluster #1 Of 1), Eukaryotic | Eukaryotes | 325 | 0.36 | Binding ≤ 10μM |
PPARA-1-E | Peroxisome Proliferator-activated Receptor Alpha (cluster #1 Of 2), Eukaryotic | Eukaryotes | 4100 | 0.30 | Functional ≤ 10μM |
PPARG-2-E | Peroxisome Proliferator-activated Receptor Gamma (cluster #2 Of 2), Eukaryotic | Eukaryotes | 76 | 0.40 | Functional ≤ 10μM |
PPARG-2-E | Peroxisome Proliferator-activated Receptor Gamma (cluster #2 Of 2), Eukaryotic | Eukaryotes | 210 | 0.37 | Functional ≤ 10μM |
Z80106-1-O | COS-1 (Kidney Cells) (cluster #1 Of 1), Other | Other | 23 | 0.43 | Functional ≤ 10μM |
Z80169-1-O | Huh-7 (Hepatocellular Carcinoma) (cluster #1 Of 1), Other | Other | 220 | 0.37 | Functional ≤ 10μM |
Z80561-1-O | U2OS (Osteosarcoma Cells) (cluster #1 Of 1), Other | Other | 30 | 0.42 | Functional ≤ 10μM |
Z81117-1-O | Keratinocytes (Keratinocytes) (cluster #1 Of 2), Other | Other | 8000 | 0.29 | Functional ≤ 10μM |
Z81135-4-O | L6 (Skeletal Muscle Myoblast Cells) (cluster #4 Of 4), Other | Other | 5000 | 0.30 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
AOFB_HUMAN | P27338 | Monoamine Oxidase B, Human | 832 | 0.34 | Binding ≤ 1μM |
PPARA_HUMAN | Q07869 | Peroxisome Proliferator-activated Receptor Alpha, Human | 140 | 0.38 | Binding ≤ 1μM |
PPARG_RAT | O88275 | Peroxisome Proliferator-activated Receptor Gamma, Rat | 325 | 0.36 | Binding ≤ 1μM |
PPARG_HUMAN | P37231 | Peroxisome Proliferator-activated Receptor Gamma, Human | 10 | 0.45 | Binding ≤ 1μM |
RXRA_RAT | Q05343 | Retinoid X Receptor Alpha, Rat | 325 | 0.36 | Binding ≤ 1μM |
AOFB_HUMAN | P27338 | Monoamine Oxidase B, Human | 832 | 0.34 | Binding ≤ 10μM |
PPARA_HUMAN | Q07869 | Peroxisome Proliferator-activated Receptor Alpha, Human | 140 | 0.38 | Binding ≤ 10μM |
PPARD_HUMAN | Q03181 | Peroxisome Proliferator-activated Receptor Delta, Human | 3620 | 0.30 | Binding ≤ 10μM |
PPARG_HUMAN | P37231 | Peroxisome Proliferator-activated Receptor Gamma, Human | 10 | 0.45 | Binding ≤ 10μM |
PPARG_RAT | O88275 | Peroxisome Proliferator-activated Receptor Gamma, Rat | 325 | 0.36 | Binding ≤ 10μM |
RARG_HUMAN | P13631 | Retinoic Acid Receptor Gamma, Human | 10000 | 0.28 | Binding ≤ 10μM |
RXRA_RAT | Q05343 | Retinoid X Receptor Alpha, Rat | 325 | 0.36 | Binding ≤ 10μM |
Z80106 | Z80106 | COS-1 (Kidney Cells) | 23 | 0.43 | Functional ≤ 10μM |
Z80169 | Z80169 | Huh-7 (Hepatocellular Carcinoma) | 220 | 0.37 | Functional ≤ 10μM |
Z81117 | Z81117 | Keratinocytes (Keratinocytes) | 8000 | 0.29 | Functional ≤ 10μM |
Z81135 | Z81135 | L6 (Skeletal Muscle Myoblast Cells) | 5000 | 0.30 | Functional ≤ 10μM |
PPARA_HUMAN | Q07869 | Peroxisome Proliferator-activated Receptor Alpha, Human | 10000 | 0.28 | Functional ≤ 10μM |
PPARG_MOUSE | P37238 | Peroxisome Proliferator-activated Receptor Gamma, Mouse | 60 | 0.40 | Functional ≤ 10μM |
PPARG_HUMAN | P37231 | Peroxisome Proliferator-activated Receptor Gamma, Human | 10 | 0.45 | Functional ≤ 10μM |
Z80561 | Z80561 | U2OS (Osteosarcoma Cells) | 30 | 0.42 | Functional ≤ 10μM |
Description | Species |
---|---|
Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | |
Free fatty acid receptors | |
G alpha (q) signalling events | |
PPARA activates gene expression | |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | |
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polyp | |
Transcriptional Regulation of Adipocyte Differentiation in 3T3-L1 Pre-adipocytes | |
Transcriptional regulation of white adipocyte differentiation |
Description | Species |
---|---|
Activation of gene expression by SREBF (SREBP) | |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | |
Circadian Clock | |
Import of palmitoyl-CoA into the mitochondrial matrix | |
Monoamines are oxidized to aldehydes by MAOA and MAOB, producing NH3 and H2O2 | |
Nuclear Receptor transcription pathway | |
PPARA activates gene expression | |
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alp | |
Regulation of pyruvate dehydrogenase (PDH) complex | |
REV-ERBA represses gene expression | |
RORA activates circadian gene expression | |
Transcriptional activation of mitochondrial biogenesis | |
Transcriptional regulation of white adipocyte differentiation | |
YAP1- and WWTR1 (TAZ)-stimulated gene expression |